TNFRSF17 and lymphoma: CD19 (four products) and B-cell maturation antigen (BCMA) (two products) are the two primary antigens targeted by CAR-T cells to treat relapsed/refractory (R/R) B-cell-derived leukemia, lymphoma, and multiple myeloma [9, 13, 16–21].